Forest, Richter Schizophrenia Drug Met Clinical Trial Goals Feb. 28 (Bloomberg) --Gedeon Richter Nyrt. (RICHT) and Forest Laboratories Inc. (FRX) said that the experimental antipsychotic drug cariprazine met the goals of two late-stage clinical trials for the treatment of schizophrenia. The companies plan to seek approval for the drug this year to treat schizophrenia and bipolar mania, [...]
Beyond Competitive Advantage - Who should be trusted to distribute a product requiring a REMS? As discussed in the New England Journal of Medicine on April 17, 2014 by Sarpatwari, Avorn, and Kesselheim, REMS are being used as a source of competitive advantage by some pharmaceutical companies. Researchers from the Brigham and Women's Hospital [...]
Postmarketing Safety Data Drives Significant Value Even in the Absence of Identified Signals – Part 1 of 3
Postmarketing Safety Data Drives Significant Value Even in the Absence of Identified Signals - Part 1 of 3 This is the first of a three part series on the value of disclosure of postmarketing safety information by pharmaceutical manufacturers. Spontaneous postmarketing safety data is typically kept confidential (there is no requirement for manufacturers to [...]
Outsourcing is a part of our daily reality in the pharmaceutical industry. Both pharmacovigilance and medical affairs are utilizing outsourced resources to a greater and greater extent. Fiore Healthcare Advisors shares experience and perspectives on how to extract appropriate value from outsourcing. Please read our piece in Life Science Leader.
A double-edged reality of the digital age: most healthcare consumers get their drug safety information from the internet. Physicians and pharmacists must be prepared to address this issue. Google searches generally turn up Wikipedia as a top source, and a recent Perspective in the New England Journal of Medicine quantified exactly what that means [...]